Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is still a highly fatal malignancy among the most common cancers. More powerful treatments are expecting to bring hope for patients. Biweekly gemcitabine/nab-paclitaxel/S-1 (GAS) was proved safe and effective for patients with locally advanced panc...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chen, Li, Xiaofen, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117556/
https://www.ncbi.nlm.nih.gov/pubmed/33985455
http://dx.doi.org/10.1186/s12885-021-08275-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117556/
https://www.ncbi.nlm.nih.gov/pubmed/33985455
http://dx.doi.org/10.1186/s12885-021-08275-9

Ejemplares similares